Exelixis Inc Restructuring Reserve
Exelixis Inc (EXEL) had Restructuring Reserve of $2.65 million as of 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Balance Sheet › Liabilities
us-gaap:RestructuringReserve · last filed 2026-02-10
- 2026-01-02: Restructuring Reserve $2.65M.
- 2025-10-03: Restructuring Reserve $16.62M.
- 2025-01-03: Restructuring Reserve $256.00K.
- 2016-12-31: Restructuring Reserve $1.94M.
| Period end | Restructuring Reserve |
|---|---|
| 2026-01-02 | $2.65M 10-K · filed 2026-02-10 |
| 2025-10-03 | $16.62M 10-Q · filed 2025-11-04 |
| 2025-01-03 | $256.00K 10-K · filed 2026-02-10 |
| 2016-12-31 | $1.94M 10-K · filed 2017-02-27 |
| 2016-09-30 | $2.23M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $3.66M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $3.53M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $4.59M 10-K · filed 2017-02-27 |
| 2014-12-31 | $10.79M 10-K · filed 2017-02-27 |
| 2014-06-30 | $10.47M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $12.23M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $13.47M 10-K · filed 2017-02-27 |
| 2013-09-30 | $13.90M 10-Q · filed 2013-10-30 |
| 2012-12-31 | $19.22M 10-Q · filed 2014-07-31 |
| 2012-09-30 | $10.49M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $11.98M 10-Q · filed 2012-08-02 |
| 2012-03-31 | $12.36M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $13.98M 10-K · filed 2014-02-20 |
| 2010-12-31 | $14.28M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |